Hoth Therapeutics, a biopharmaceutical company focused on patient care, has recently received protocol approval for its cancer therapeutic, HT-001. This exciting development was announced on July 19, 2023.
The FDA-approved trial now has two sites approved for conducting the study, and additional sites are currently in the approval process. This means that recruitment of patients can now be accelerated.
Hoth Therapeutics is dedicated to finding innovative solutions for cancer treatment and is thrilled to have reached this milestone in their Phase 2a clinical trial of HT-001.
During the trial, participants will apply HT-001 Gel once per day for a period of six weeks. The effectiveness of the gel in treating acneiform rash and other skin disorders induced by EGFRI therapy will be evaluated using various assessment tools. These tools will measure the severity of rash, pain, itching (pruritus), and other relevant factors.